AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q4 FY23 results · Jan–Mar 2023
AstraZeneca Pharma India reported revenue from operations of ₹284.70 crore (up 22.7% from Q4 FY22) and net profit of ₹17.27 crore (down 38.3% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a standalone basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 284.70 | 231.96 | +22.7% | 249.81 | +14.0% |
| Other income | 8.00 | 3.68 | +117.1% | 7.20 | +11.1% |
| Total income | 292.70 | 235.65 | +24.2% | 257.00 | +13.9% |
| Profit before tax | 23.28 | 37.03 | −37.1% | 39.46 | −41.0% |
| Net profit for the period | 17.27 | 27.98 | −38.3% | 29.30 | −41.1% |
| EPS, basic (₹) | 6.91 | 11.19 | −38.3% | 11.72 | −41.1% |
| Net margin (%) | 6.1 | 12.1 | 11.7 |
Standalone
- Filed with BSE
- 30 May 2023, 17:37 IST
- Board meeting
- 30 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE